Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action

The receptor tyrosine kinase HER2 acts as oncogenic driver in numerous cancers. Usually, the gene is amplified, resulting in receptor overexpression, massively increased signaling and unchecked proliferation. However, tumors become frequently addicted to oncogenes and hence are druggable by targeted...

Descripción completa

Detalles Bibliográficos
Autores principales: Kast, Florian, Schwill, Martin, Stüber, Jakob C., Pfundstein, Svende, Nagy-Davidescu, Gabriela, Rodríguez, Josep M. Monné, Seehusen, Frauke, Richter, Christian P., Honegger, Annemarie, Hartmann, Karen Patricia, Weber, Thomas G., Kroener, Felix, Ernst, Patrick, Piehler, Jacob, Plückthun, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213836/
https://www.ncbi.nlm.nih.gov/pubmed/34145240
http://dx.doi.org/10.1038/s41467-021-23948-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213836/
https://www.ncbi.nlm.nih.gov/pubmed/34145240
http://dx.doi.org/10.1038/s41467-021-23948-6

Ejemplares similares